Nanowired Delivery of Curcumin Attenuates Methamphetamine Neurotoxicity and Elevates Levels of Dopamine and Brain-Derived Neurotrophic Factor

Overview

Journal Adv Neurobiol

Publisher Springer

Date 2023 Jul 22

PMID 37480467

Authors

Ilaria Ottonelli

Aruna Sharma

Barbara Ruozi

Giovanni Tosi

Jason Thomas Duskey

Maria Angela Vandelli

Jose Vicente Lafuente

Ala Nozari

Dafin Fior Muresanu

Anca Dana Buzoianu

Z Ryan Tian

Zhiqiang Zhang

Cong Li

Lianyuan Feng

Lars Wiklund

Hari Shanker Sharma

Affiliations

Soon will be listed here.

Abstract

Curcumin is a well-known antioxidant used as traditional medicine in China and India since ages to treat variety of inflammatory ailments as a food supplement. Curcumin has antitumor properties with neuroprotective effects in Alzheimer's disease. Curcumin elevates brain-derived neurotrophic factor (BDNF) and dopamine (DA) levels in the brain indicating its role in substance abuse. Methamphetamine (METH) is one of the most abused substances in the world that induces profound neurotoxicity by inducing breakdown of the blood-brain barrier (BBB), vasogenic edema and cellular injuries. However, influence of curcumin on METH-induced neurotoxicity is still not well investigated. In this investigation, METH neurotoxicity and neuroprotective effects of curcumin nanodelivery were examined in a rat model. METH (20 mg/kg, i.p.) neurotoxicity is evident 4 h after its administration exhibiting breakdown of BBB to Evans blue albumin in the cerebral cortex, hippocampus, cerebellum, thalamus and hypothalamus associated with vasogenic brain edema as seen measured using water content in all these regions. Nissl attaining exhibited profound neuronal injuries in the regions of BBB damage. Normal curcumin (50 mg/kg, i.v.) 30 min after METH administration was able to reduce BBB breakdown and brain edema partially in some of the above brain regions. However, TiO nanowired delivery of curcumin (25 mg/kg, i.v.) significantly attenuated brain edema, neuronal injuries and the BBB leakage in all the brain areas. BDNF level showed a significant higher level in METH-treated rats as compared to saline-treated METH group. Significantly enhanced DA levels in METH-treated rats were also observed with nanowired delivery of curcumin. Normal curcumin was able to slightly elevate DA and BDNF levels in the selected brain regions. Taken together, our observations are the first to show that nanodelivery of curcumin induces superior neuroprotection in METH neurotoxicity probable by enhancing BDNF and DA levels in the brain, not reported earlier.

Citing Articles

Recent advances in self-targeting natural product-based nanomedicines.

Liu H, Jin X, Liu S, Liu X, Pei X, Sun K J Nanobiotechnology. 2025; 23(1):31.

PMID: 39833846 PMC: 11749302. DOI: 10.1186/s12951-025-03092-9.

References

Steinkellner T, Freissmuth M, Sitte H, Montgomery T . The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem. 2011; 392(1-2):103-15. PMC: 4497800. DOI: 10.1515/BC.2011.016. View

Rawson R, Shoptaw S, Ling W . Management of methamphetamine abuse and dependence. Curr Psychiatry Rep. 2006; 8(5):345-54. DOI: 10.1007/s11920-006-0035-x. View

Homer B, Solomon T, Moeller R, Mascia A, DeRaleau L, Halkitis P . Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull. 2008; 134(2):301-10. DOI: 10.1037/0033-2909.134.2.301. View

Romanelli F, Smith K . Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006; 26(8):1148-56. DOI: 10.1592/phco.26.8.1148. View

Cho A, Melega W . Patterns of methamphetamine abuse and their consequences. J Addict Dis. 2002; 21(1):21-34. DOI: 10.1300/j069v21n01_03. View

Murray J . Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol. 1998; 132(2):227-37. DOI: 10.1080/00223989809599162. View

Buttner A . Neuropathological alterations in cocaine abuse. Curr Med Chem. 2012; 19(33):5597-600. DOI: 10.2174/092986712803988947. View

Brownlow H, Pappachan J . Pathophysiology of cocaine abuse. Eur J Anaesthesiol. 2002; 19(6):395-414. DOI: 10.1017/s0265021502000650. View

Romero-Martinez A, Moya-Albiol L . Neuropsychological impairments associated with the relation between cocaine abuse and violence: neurological facilitation mechanisms. Adicciones. 2015; 27(1):64-74. View

10.

Roncero C, Abad A, Padilla-Mata A, Ros-Cucurull E, Barral C, Casas M . Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse. Curr Neuropharmacol. 2016; 15(2):315-323. PMC: 5412693. DOI: 10.2174/1570159x14666160324144912. View

11.

Gonzales R, Mooney L, Rawson R . The methamphetamine problem in the United States. Annu Rev Public Health. 2010; 31:385-98. PMC: 4440680. DOI: 10.1146/annurev.publhealth.012809.103600. View

12.

Shukla R, Crump J, Chrisco E . An evolving problem: methamphetamine production and trafficking in the United States. Int J Drug Policy. 2012; 23(6):426-35. DOI: 10.1016/j.drugpo.2012.07.004. View

13.

Jayanthi S, Daiwile A, Cadet J . Neurotoxicity of methamphetamine: Main effects and mechanisms. Exp Neurol. 2021; 344:113795. PMC: 8338805. DOI: 10.1016/j.expneurol.2021.113795. View

14.

Courtney K, Ray L . Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2014; 143:11-21. PMC: 4164186. DOI: 10.1016/j.drugalcdep.2014.08.003. View

15.

Kuczenski R, Segal D, Cho A, Melega W . Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci. 1995; 15(2):1308-17. PMC: 6577819. View

16.

Numachi Y, Ohara A, Yamashita M, Fukushima S, Kobayashi H, Hata H . Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol. 2007; 572(2-3):120-8. DOI: 10.1016/j.ejphar.2007.06.022. View

17.

Asser A, Taba P . Psychostimulants and movement disorders. Front Neurol. 2015; 6:75. PMC: 4403511. DOI: 10.3389/fneur.2015.00075. View

18.

Abbruscato T, Trippier P . DARK Classics in Chemical Neuroscience: Methamphetamine. ACS Chem Neurosci. 2018; 9(10):2373-2378. DOI: 10.1021/acschemneuro.8b00123. View

19.

Blum K, Cadet J, Gold M . Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch. J Neurol Sci. 2020; 420:117252. DOI: 10.1016/j.jns.2020.117252. View

20.

Schwarzbach V, Lenk K, Laufs U . Methamphetamine-related cardiovascular diseases. ESC Heart Fail. 2020; 7(2):407-414. PMC: 7160483. DOI: 10.1002/ehf2.12572. View